StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by Str8Shuteron Jul 31, 2020 10:13am

91 Views

Post# 31349257

RE:RE:RE:Poop in a box

It was a pretty legitimate question, actually. The answer probably lies in the EXAS Q2 earnings report and/or MD&A.

Skrit37 wrote:

okletsmakemoney wrote: In what area could they have be losing so much net loss, when there's an increase of revenue? Could it be the investment on new covid equippements? I hope SZLS wouldn't have the same situation since our lab has the equippment already, right?

Why do you see Nails post negatively....why not see it as wow!!!!.they made a ton of money on PCR testing so far...mabye szls can also profit the same way... but scaled down version.....